Boehringer Ingelheim Program 1

About Numab Innovation

Numab Therapeutics is a Zurich-based biotech pioneering a rational, platform-based approach to design multispecific antibodies with tailored pharmacokinetics. The company's core value proposition lies in its proprietary λ-Cap™ and MATCH™ technologies, which enable the reproducible creation of novel therapeutics intended to overcome limitations of first-generation antibodies. It is advancing a proprietary pipeline led by NM26 for atopic dermatitis while simultaneously validating its platform through multiple high-value collaborations with partners like Boehringer Ingelheim and Kaken Pharmaceutical. The recent appointment of a seasoned CEO with significant commercial and deal-making experience signals a maturation phase focused on pipeline advancement and strategic partnerships.

Therapeutic Areas

Other Retinal Diseases Drugs